MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)
- DOI
- 10.1016/s2152-2650(22)01570-1
- Published
- 2022-10
- Container
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2152-2650-22-01570-1,
title = {MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)},
author = {Rodrigo Ito and Toby A. Eyre and Nirav N. Shah and Steven Le Gouill and Martin Dreyling and Elisabeth Vandenberghe and Wojciech Jurczak and Yucai Wang and Chan Y. Cheah and Mitul Gandhi and Christopher Chay and Jeff Sharman and David J. Andorsky and Yuqin Song and Amy Stark and Valerie Muthig and Michael L. Wang},
year = {2022},
journal = {Clinical Lymphoma Myeloma and Leukemia},
doi = {10.1016/s2152-2650(22)01570-1},
url = {https://doi.org/10.1016/s2152-2650(22)01570-1}
}RIS
TY - JOUR TI - MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress) AU - Rodrigo Ito AU - Toby A. Eyre AU - Nirav N. Shah AU - Steven Le Gouill AU - Martin Dreyling AU - Elisabeth Vandenberghe AU - Wojciech Jurczak AU - Yucai Wang AU - Chan Y. Cheah AU - Mitul Gandhi AU - Christopher Chay AU - Jeff Sharman AU - David J. Andorsky AU - Yuqin Song AU - Amy Stark AU - Valerie Muthig AU - Michael L. Wang PY - 2022 JO - Clinical Lymphoma Myeloma and Leukemia DO - 10.1016/s2152-2650(22)01570-1 UR - https://doi.org/10.1016/s2152-2650(22)01570-1 ER -
APA
Ito, R., Eyre, T. A., Shah, N. N., Gouill, S. L., Dreyling, M., Vandenberghe, E., Jurczak, W., Wang, Y., Cheah, C. Y., Gandhi, M., Chay, C., Sharman, J., Andorsky, D. J., Song, Y., Stark, A., Muthig, V., & Wang, M. L. (2022). MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress). Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/s2152-2650(22)01570-1
Source records
- crossref · retrieved 2026-09-25T23:08:25.486Z